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A 5′FR/G-260C (NCBI reference: 010393.16:g.15983174CNG) functional polymorphism of Multidrug Resistance-associated Protein 1
(ABCC1) promoter has been reported which influences ABCC1 expression including inflammatory related events.
We aimed at investigating the impact of this polymorphism on the severity of CF disease.
In this multicentric study, key clinical features of 203 CF patients homozygous for the F508del mutation were recorded. Kaplan–Meier
analysis showed that patients with the rare CC genotype were chronically colonized by PA around 6 years earlier (mean±SD: 11.2 year±7.8, 95%
CI for the mean: 5.7–16.8) than those with the GG or the CG alleles (pb=0.01) and a FEV1 b60% predicted was first observed earlier in this
group (pb0.05). Concordant trends to better nutritional status and FEV1 were observed in the slightly older GG subgroup.
The potential role of ABCC1 promoter as a modifier gene deserves further study.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: NT_010393.16:g.15983174CNG polymorphism; Cystic fibrosis; Infection by Pseudomonas aeruginosa; Modifier gene; Multidrug Resistance-associated
Protein 1; ABCC1; Severity of cystic fibrosis disease1. Introduction
Cystic fibrosis (CF) is the most common fatal inherited
disorder in white population. It is caused by mutations in the CF
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1569-1993/$ - see front matter © 2011 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2010.10.007the ATP Binding Cassette (ABC) transporter superfamily. CF is
mainly characterized by bronchopulmonary disease, pancreatic
insufficiency and male infertility. It presents over a wide range of
disease severity and patients with identical CF genotypes can
display markedly different phenotypic expression [1,2].
Among the ABC transporter superfamily, Multidrug
Resistance-associated Protein 1 (MRP-1) and CFTR share the
highest homology. MRP-CFTR regulatory interaction has been
reported [3]. Studies focusing onMRP-1 (now defined asABCC1,
according to the international nomenclature) have suggested that
it may possibly represent a CF modifier gene [4–9]. Data
obtained from the Verona Centre have demonstrated induction
of ABCC1 mRNA and restoration of nasal potential differenced by Elsevier B.V. All rights reserved.
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suggesting that functional complementation of mutant CFTR
by ABCC1 could possibly contribute, at least partly, to the
mechanism of action of this macrolide. This finding, however,
has not been confirmed by others [10].
More recently, a functional polymorphism in ABCC1
promoter (NBCI reference: NT_010393.16:g.15983174CNG;
accession number on NIH SNP database: rs504348) that can
possibly modulate the protein expression has been reported
[12,13]. Accordingly, in four cell lines, the G allele of this
polymorphism was associated with a significantly lower
transcriptional activity of the promoter than the C allele [13].
We hypothesized that ABCC1 polymorphism is associated
with the severity of CF disease. In this study we determined the
NT_010393.16ABCC1 genotype in a large cohort of F508del
homozygous CF patients and analyzed the association of C or G
alleles with CF disease severity. Gene reporter assays were
performed in order to establish the relevance of the
NT_010393.16 variant for the ABCC1 promoter transcriptional
activity. In a subgroup of CF patients, allelic frequencies were
considered in relation with ABCC1 mRNA levels and cAMP
responsiveness in nasal epithelial cells.
2. Materials and methods
2.1. Genotyping
DNAwas extracted from whole blood using salting out method
then samples were genotyped for the NT_010393.16:
g.15983174CNG (cluster report: rs1805010). Polymorphism of
ABCC1 promoter region of interest (−365/−211) was amplified
with Polymerase Chain Reaction (PCR) in a GeneAmp PCR
system 9700® (Applied Biosystem, Foster City, CA, USA) using
the forward primer 5′FR (5′-CAGGATGAAATGAGGGCA-
CAG) and the reverse primer 5′FR (5′-GAAGCGCCTGG-
GATCTTTGG) as previously described [13]. Reactions were
performed with AmpliTaq Gold ® (Applied Biosystem), in
AmpliTaq Buffer 1×, 1.5 mM Mg2+, 200 μM of each dNTP,
10 pmol of each primer in presence of 80 ng of DNA in a final
volume of 50 μl. The temperatures applied were: 94 °C for 15′
followed by 35 cycles of 94 °C for 30″, 62 °C for 90″ and 72 °C for
60′ finally followed by 72 °C for 10′. The size of the PCR fragment
was checked by electrophoresis on 2% agar-gel in the presence of
Size Marker VI (Roche, Diagnostics, Mannheim, Germany). The
fragment was then purified using ExoSAP-IT® (Usb-corporation,
Cleveland,Ohio,USA) according tomanufacturer's instructions. A
dry sample containing 2 μl of purified PCR fragment and 1 μl of
4 mMprimer sequencing R (5′-CCTGCGACCACTTTTCAAAT)
was provided for analyses of polymorphism that was carried out
using SnapShot® Multiplex system (Applied Biosystem; BMR
Genomics sequencing service C.R.I.B.I.'s University of Padova).
Results were analysed using GenescanView 1.2 software.
2.2. Cell lines
The following airway epithelial cell lineswere used: 2CFSMEo,
a CF tracheobronchial gland epithelial cell line kindly provided byD. Gruenert, University of California, CA, USA [14]; IB3-1, a CF
respiratory epithelial cell line and C38, its corresponding rescued
isogenic cell line expressing a plasmid encoded copy of functional
CFTR; both were kind gifts of Pamela Zeitlin, Johns Hopkins
University, USA [15]. 2CFSMEo cells were grown in Eagle's
MEM (Cambrex Bio Science, Verviers, Belgium) supplemented
with 10% foetal bovine serum (FBS, Cambrex Bio Science) and
1% L-glutamine (Cambrex Bio Science). IB3-1 and C38 were
cultured in LHC-8 media (Biosource, Camarillo, CA, USA)
supplemented with 5% FBS. Cell lines were cultured at 37 °C in a
humidified atmosphere with 5% CO2.2.3. In vitro analysis of promoter SNP NT_010393.16
The promoter SNP NT_010393.16-reporter constructs for
this study were kindly provided by Dr. Caroline Lee from
National Cancer Centre of Singapore [12]. A 635 bp promoter
region of ABCC1 gene including the SNP region was inserted
upstream of the β-galactosidase reporter gene in an expression
vector which also contains the enhanced green fluorescent
protein (EGFP) reporter gene driven by cytomegalovirus
promoter for normalization against differences in transfection
efficiency. Promoter–reporter constructs were transiently
transfected using Fugene Hd (Roche).
EGFP fluorescence was measured in cellular lysates with a
485 nm excitation filter and a 530 emission filter with a Packard
fluoroCOUNTER (PerkinElmer Inc., Waltham, Massachusetts,
USA). β-galactosidase activity was quantified by means of a
colorimetric assay (β-galactosidase reporter gene activity
detection Kit, Sigma-Aldrich, St. Louis, MO, USA) with
ONPG (O-Nitrophenyl-β-D-galactopyranosid) as substrate. The
reaction was detected 4 h after incubation at 37 °C in a Packard
SpectraCOUNTER (PerkinElmer Inc.) microplate reader at
405 nm. Values were normalized against blank and the
corresponding cell lines were transfected with an empty vector.
β-galactosidase expression was normalized against EGFP
activity.2.4. Nasal brushing, mRNA quantification and anion
conductance assays
The procedures were performed as previously described
[9,16]. A halide-sensitive videoimaging assay with fluorescent
dye 6-methoxy-N-3′-sulfopropylquinolinium (SPQ, Molecular
Probe, Cedex, France) was used to measure chloride transport at
the cellular level. After loading with 10 mM SPQ, cells were
continuously perfused with isotonic NaI solution, followed by
NaNO3 solution to which cAMP agonists were added. The
maximum change in fluorescence rate after addition of cAMP
agonists was defined as cAMP-dependent anion conductance
(ΔFcAMP/Δt) and the CFTR-mediated cAMP-stimulated
anion conductive pathway was considered present when
ΔFcAMP/ΔtN0.1. At least 5 nasal ciliated cells (NCC) were
studied in each cell preparation experiment. The percentage of
cells displaying cAMP response (%cAMP) in each individual
experiment represented the SPQ assay endpoint.
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209 CF patients, all homozygous for the F508del mutation,
were recruited from three European centres (Verona: 138,
Brussels: 51, and Paris: 20). They were aged from 6 to 40 years
and all had reliable spirometry. Functional in vivo studies were
performed from nasal brushing samples collected from 20 CF
patients from the Paris centre. Genotype for the NT_010393.16
polymorphism of ABCC1 was determined in 130 adult non-CF
Italian subjects and in all 209 CF patients. Healthy subjects
were negative for the most common mutations of CFTR gene
except for 4 heterozygous subjects (healthy carriers), consis-
tently with epidemiological data about carrier frequency.
Informed signed consent for the use of DNA and other
samples was obtained following approval by local Ethical
Committees.2.6. Clinical data of CF patients
Clinical data were of 203 patients collected thanks to
electronic databases. Main characteristics are shown in Table 1.
Anthropometric parameters and FEV1 were normalized using
Freeman's [17] and Knudson's [18] equations respectively.
Diabetes was defined by the need for insulin therapy.
Chronic Pseudomonas aeruginosa (PA) colonization was
reported using the European consensus definition [19]. In
order to take into account the accelerated FEV1 decline with age
in CF patients, the last value of FEV1 was also expressed as
FEV1 percentile using CF-specific reference equations [20].
Outcome variables were then stratified in quartiles. Upper and
lower quartiles from each centre were then pooled for further
statistical analysis.2.7. Statistical analysis
For in vitro functional studies, the correlation between ABCC1
genotype and ABCC1 mRNA expression or percent nasal
potential both under basal conditions and after cAMP stimulationTable 1
Characteristics of 203 CF patients homozygous for the F508del mutation
recruited from 3 different European centres.
Paris (Necker) Brussels (St Luc) Verona
Subjects n 14 51 138
Male/female 8/6 29/22 60/78
Age years 17.43±3.32 21.33±9.65 24±9.44




Weight Z score −1.95±1.64 −0.98±1.16 −1.01±1.40
Height Z score −0.85±1.75 −0.9±1.18 −0.69±1.22
BMI Z score −1.45±1.19 −0.61±1.03 −0.82±1.28
cc by PA n (%) 6 (42.9%) 16 (31.4%) 88 (63.8%)
Diabetes n (%) 0 10 (19.6%) 37 (26.8%)
Data are presented as mean±SD unless otherwise stated. FEV1: forced
expiratory volume in one second; and cc by PA: chronic colonization by
Pseudomonas aeruginosa.was assessed using the t test with Welch's correction where
variances were found to be significantly different.
Clinical data were compared using chi-squared test for
categorical variables and unpaired t test or Mann–Whitney test
for continuous variables, as appropriate. Chi-square was also
used to compare allelic distribution between upper and lower
quartiles. Kaplan–Meier plot was obtained for ages at chronic
colonization by PA and at first FEV1 value b60% predicted,
under stable conditions.
3. Results
3.1. ABCC1 SNPNT_010393.16 genotyping
Among 130 healthy control subjects, the observed frequen-
cies for CC, CG and GG polymorphic genotypes were 4%, 39%
and 57% respectively. The distribution was similar to that
observed in 209 CF patients (5.9%, 38.9% and 55.2%) and in
keeping with that reported by Wang and colleagues in a
European non-CF population [13].
3.2. Functional in vitro analysis
IB3-1 and C38 cell lines were efficiently transfected, as
detected by EGFP fluorescence, but β-galactosidase activity
was undetectable. In 2CFSMEo-cells, repeated assays showed
no statistically significant difference of regulation by the major
allele G-containing promoter when compared with the C-allele.
3.3. Functional in vivo/ex vivo analysis
mRNA quantification and anion conductance assays in the
subgroup of 20 patients from the Paris centre did not show any
significant difference between GG and GC genotypes mRNA
levels (p=0.1152;%BASAL p=0.1911; after cAMP p=0.4964).
3.4. Clinical status of CF patients and genotype for the
NT_010393.16 polymorphism of ABCC1
No significant difference could be demonstrated between
anthropometric data, FEV1, diabetes prevalence and the
genotype for the NT_010393.16 polymorphism of ABCC1.
However, there was a slight but concordant trend for the GG
group to have higher height Z score, weight Z score, BMI Z
score and better FEV1 (Table 2).
In the study group, 110 CF patients (54%) were chronically
colonized by PA. Rates of chronic colonization by PA were
comparable in the three groups. Age at chronic colonization by
PA was available for 103 out 110 CF patients. Kaplan–Meier
analysis showed that patients harbouring the CC genotype were
chronically colonized by PA around 6 years earlier (mean±SD:
11.2 year±7.8, 95% CI for the mean: 5.7–16.8) than those with
the GG or the CG alleles (pb=0.01, Fig. 1).
When comparing upper and lower quartiles for normalized
FEV1, no genotype for the NT_010393.16 polymorphisms of
ABCC1 (CC, CG or GG) was found to be overrepresented in
any subgroup (Table 3).
Table 2
Clinical data of 203 CF patients homozygous for the F508 del mutation
according to the genotype for the NT_010393.16:g.15983174CNG
polymorphism of ABCC1.
CC GC GG CC versus
GG p-value
n 12 79 112
Age (years±SD) 21.5±6.9 22.46±9.5 23.3±9.5 0.24
Height — Z score −0.84±1.45 −0.79±1.28 −0.72±1.21 0.76
Weight — Z score −1.35±2.13 −1.21±1.37 −0.93±1.28 0.32
BMI — Z score −0.97±1.88 −0.91±1.20 −0.70±1.16 0.47
FEV1 — % predicted 61.7±37.8 61.1±29.4 67.3±27 0.52
cc by PA — n (%) 10 (83.3%) 39 (49.4%) 61 (54.5%) 0.11
Age at cc by
PA — years
11.2±7.8 16.8±7.8 17±9.1 0.0644
Diabetes — n (%) 3 (25%) 17 (21.5%) 28 (25%) 0.73
Data are presented as mean±SD unless otherwise stated. FEV1: forced
expiratory volume in one second; BMI: body mass index; and cc by PA: chronic
colonization by Pseudomonas aeruginosa.
Table 3
Comparison of upper (UQ) and lower (LQ) quartiles according to the Kulich's
CF specific FEV1 reference values.
UQ LQ p-value
n 48 50
Male/female 27/21 19/31 0.11
Age — years 21.21±7.66 24.1±8.47 0.08
FEV1 — % predicted 95±14 33±18 b0.0001
FEV1 — CF specific percentile 88±8 13±15 b0.0001
Weight — Z score −1.06±1.57 −1.72±1.37 0.0286
Height — Z score −1.15±1.16 −0.61±1.38 0.0378
BMI — Z score −0.44±1.23 −1.67±1.14 b0.0001
cc by PA — n (%) 18 (37.5%) 36 (72%) 0.0012
Diabetes — n (%) 4 (8.3%) 22 (44%) 0.0002
ABCC1 genotype n (%)
CC 5 (10.4%) 4 (8%) 0.95
CG 18 (37.5%) 24 (48%) 0.40
GG 25 (52.1%) 22 (44%) 0.55
Data are presented as mean±SD unless otherwise stated. FEV1: forced
expiratory volume in one second; BMI: body mass index; and cc by PA: chronic
colonization by Pseudomonas aeruginosa.
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below 60% predicted under stable conditions was significantly
lower in patients with CC genotype in comparison with CG or
GG (pb0.05) (Fig. 2).
4. Discussion
To the best of our knowledge this is the first study looking at
the potential role of ABCC1 single nucleotide polymorphisms in
CF patients.
Clinical data from the present study show that in patients
homozygous for the F508 del mutation, the rare CC phenotype
of the NT_010393.16:g.15983174CNG polymorphism of
ABCC1 promoter region is associated with a significantly
younger age at which a FEV1 b60% predicted is first observed
under stable conditions and a younger age at chronic
colonization by PA. Age at first PA infection and age at chronic
colonization by PA have both been used in other studies of
modifier genes in CF [21,22] but the latter is more meaningful as
chronic colonization by PA has been clearly associated with anFig. 1. Age at chronic P. aeruginosa infection according to ABCC1 genotype.
Kaplan–Meier plots relative to age at chronic infection by P. aeruginosa in
patients with CC, GG and GC alleles (n=103) show different trends for CC
versus GG and GC (P=0.0065 and P=0.0056 respectively).accelerated rate of FEV1, poorer survival and increased costs of
treatment [23–26]. In addition, concordant trends to better
nutritional status and FEV1 were observed in the slightly older
GG subgroup.
Beside or together with environmental factors (including
therapies), modifier genes are believed to contribute to the
variable clinical severity of CF in patients sharing the same
CFTR genotype. However, studies looking at CF modifier
genes have often yielded conflicting results. Even though the
reasons for this are not fully understood, it is clear that many
small studies are underpowered [27–29].
In order to circumvent common pitfalls, our multicenter
study focused on a single CFTR genotype and investigated a
large population size of more than 200 patients. Participating
centres have long been used reliable CF-specific electronic
databases.
Efforts were made to normalize data and to use clear
definitions and standardized reference values [17–20]. ClinicalFig. 2. Lung function decline according to ABCC1 genotypes. Kaplan–Meier
plots relative to age at first episode with FEV1 b60% of predicted value in
patients with CC, GG and GC alleles (n=153) are shown. The overall difference
between the three curves is also significant (P=0.024), with a significant trend
towards worse prognosis from GG to CC (P=0.015).
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parameters in the whole population and stratifying patient
subgroups according to the genotype for the NT_010393.16
polymorphism of ABCC1, but also by looking at possible
overrepresentation of a given genotype in upper and lower
quartiles according to FEV1 percentiles using CF-specific
reference equations for age, height and gender [20]. The latter
approach was initially performed at each centre reducing
possible influences of local policies. In addition, two laboratory
studies were conducted in parallel that could contribute to
interpret clinical results.
It should be stressed however that given the (expected) wide
range of normalized FEV1 values, the study remained under-
powered to detect a 10% FEV1 difference which would be
accepted as significant. The low frequency of NT_010393.16
polymorphism further affects the power of the statistical analyses.
In the present study, laboratory investigations do not provide
additional support to the hypothesis of an impact of polymor-
phism on promoter transcriptional activity, mRNA levels, basal
and cAMP-induced anion transport. However, based on our
experimental model (airway tract cell lines) we cannot formally
exclude that an upstream element associated in cis with the C
allele (not included in our gene reporter construct) could inhibit
the transcriptional activity. In four epithelial cell lines not deriving
from the respiratory tract transfected with constructs containing
either C or G alleles at the position of ABCC1 SNP, Wang et al.
demonstrated a lower ABCC1 activity in G-containing promoter
cells [13]. This was not observed in the present study but a tissue
specific regulatory effect on the ABCC1 mRNA levels and
function of the NT_010393.16 ABCC1 in the lung, which is not
detectable in the primary human nasal cells, could be hypothe-
sized. It is also important to stress that only 2 out of 20 patients
who underwent nasal brushings for in vivo functional analysis
displayed the CC genotype.
ABCC1 not only plays a role in protecting cells against drugs,
toxins and heavy metals but also contributes to antioxidative
defense system and inflammation which is believed to play a
major role in the pathophysiology of CF lung disease.
In mice lacking the multidrug resistance-associated protein,
Wijnholds et al. reported a decreased response to inflammatory
stimulus [11]. Interestingly, Schultz et al. noted that in mice, loss
of the abcc1 gene results in increased resistance to Strepococcus
pneumoniae induced pneumonia [30]. In triple knock-out mice
lacking the gene for abcc1, van der Deen et al. observed a reduced
inflammatory response to cigarette smoke and lower levels of
several cytokines and chemokines in the lungs, independent of
smoke exposure [31]. More recent data confirmed an association
between ABCC1 single nucleotide polymorphisms and FEV1 in
two independent COPD cohorts, consistent with a detrimental
effect of higher ABCC1 expression [12].
Our finding of a possible deleterious effect of the CC
genotype in CF patients is in keeping with these studies.
We do believe that this issue deserves further work. Would
another team be interested in pursuing the investigation in much
larger study populations, we would be pleased to offer them our
complete set of well defined clinical and genetic data in order to
increase the power of the study.Acknowledgements
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